ATCC 100 Years Logo Anniversary ATCC 100 Years Logo Anniversary Cart 0
  • Careers
  • Support
Therapeutic antibody blocking PD-1

Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Gaylord National Resort & Convention Center, National Harbor, Maryland

November 05, 2025 - November 09, 2025

The SITC Annual Meeting brings together a global community of scientists focused on cancer immunotherapy and tumor immunology. Though ATCC is not exhibiting at the event this year, our expert scientists will be presenting four posters showcasing our reporter-labeled cells for immuno-oncology. Join our poster presentations (stay tuned for more details!) and explore our resources below to learn about our immune checkpoint reporter cells, CAR-T luciferase reporter cells, ThawReady™ products, 2-D and 3-D patient-derived cancer models, and more!

Want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.


Contact us

Browse our featured resources

CAR-T cells, CAR-Target, CD19, CD20, HER2 Application note

Luciferase Reporter Cancer Cell Lines Facilitate CAR-T Development

This report describes ATCC luciferase reporter solid and liquid tumor cell lines that express tumor antigens such as CD19, CD20, and HER2. Learn how you can incorporate these target cells into your T-Cell cytotoxicity assays to enable your breakthroughs in immuno-oncology.

More
Immune checkpoint inhibitors: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell blocked by therapeutic antibodies Application note

GAS-LUC2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors

This study demonstrates the use of three robust, responsive, and reproducible GAS-Luc2 reporter solid tumor cell lines for the assessment of T cell and other immune/tumor microenvironmental cell-mediated immune responses triggered by PD-1/PD-L1, CD-155/TIGIT, or B7-H3 (CD276) immune checkpoints.

More
immune checkpoint inhibitor Brochure

Checkpoint Luciferase Reporter Cells

To facilitate large-scale drug discovery of immune checkpoint inhibitors, ATCC created tumor and immune cell lines with high endogenous expression of checkpoint inhibitory and co-stimulatory expression levels.

More
Fluorescent blue and green spheres of leukemic cells. Brochure

THP-1 Reporter Cells

ATCC introduced luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. The THP-1 LUC2 cell lines provide a means to confidently measure immune modulation for all your drug discovery and development efforts.

More
CAR-T cells, CAR-Target, CD19, CD20, HER2 Brochure

CAR-T Target Luciferase Reporter Cells

ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.

More
Immune checkpoint inhibitors: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell blocked by therapeutic antibodies Brochure

Immuno-oncology Capabilities

ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.

More

Contact us today!

ATCC stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.





We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form has been successfully submitted